Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cocaine esterase - Tonix Pharmaceuticals Holding Corp

Drug Profile

Cocaine esterase - Tonix Pharmaceuticals Holding Corp

Alternative Names: Cocaine esterase; RBP 8000; T172R/G173G cocaine esterase; T172R/G173Q double-mutant cocaine esterase; TNX 1300

Latest Information Update: 29 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Columbia University; University of Kentucky; University of Michigan
  • Developer Indivior
  • Class Antidotes; Carboxylic ester hydrolases
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cocaine-related disorders

Most Recent Events

  • 23 May 2019 Tonix Pharma in-licenses cocaine esterase from Columbia University
  • 24 Jun 2018 Biomarkers information updated
  • 22 Feb 2016 Phase-II development is ongoing in USA
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top